Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer

Oncologist

Volumn 18, Issue 6, 2013, Pages 687-688

  Vuky, Jacqueline ^a   Corman, John M ^b   Porter, Christopher ^b   Olgac, Semra ^b   Auerbach, Evan ^b   Dahl, Kathryn ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; EXPLORATORY BEHAVIOR; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL LINE, TUMOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM GRADING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879489907     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0234     Document Type: Article

References (13)

1. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
2. Soh S, Kattan MW, Berkman S et al. Has there been a recentshift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-2218.
3. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostatecancer. J Urol 1993;150:110-114.
4. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160:2428-2434.
5. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
6. Higano CS, Corman JM, Smith DC et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapyfor metastatic hormone-refractory prostate cancer. Cancer 2008; 113:975-984.
7. Beer TM, Garzotto M, Lowe BA et al. Phase I studyofweeklymitoxantroneanddocetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004;10:1306-1311.
8. Febbo PG, Richie JP, George DJ et al. Neoadju-vantdocetaxel before radical prostatectomyin patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-5240.
9. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology2004;63:1138-1142.
10. Vuky J, Porter C, Isacson Cet al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patientswith high-risk, locally advanced prostate cancer. Cancer 2009;115: 784-791.
11. Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup ofa randomized trialof0ver-sus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170: 791-794.
12. Kantoff PW, Higano CS, Shore ND et al. Sip-uleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
13. Borrello IM, Levitsky HI, Stock Wet al. Gran-ulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009; 114:1736-1745.